Overview
Delivering advanced therapies to patients who need them requires an effective transition from lab-based cell therapy activity to manufacturing at scale. Robust, reproducible processes that can adapt to increasing demand is key to ensure success from early-stage research to commercial production.
In this GEN webinar, Nik Ekman will discuss critical considerations for scaling cell therapy processes from research through to commercialization. During the webinar, you will learn how designing flexible, closed, compliant workflows early drives efficiency, quality, and sterility assurance across cell therapy development. Some key takeaways from the webinar include:
- Key scaling considerations through each stage of the cell therapy development pipeline— from preclinical research, clinical trials, to commercialization.
- The impact of designing scalable and flexible workflows early in development to ensure efficiency, quality, and regulatory compliance later in the product lifecycle.
- The role of sterile connector technology for enabling closed-system processing to support sterility assurance and reduce risk across critical cell therapy applications.